HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) In Brief TRACK Discussion: Submit a Comment TRACK Discussion: View Comments Alert me when this article is cited Alert me when TRACK Comments are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levri, K. M. Articles by Wilson, S. A. Search for Related Content PubMed PubMed Citation Articles by Levri, K. M. Articles by Wilson, S. A.

Metformin as Treatment for Overweight and Obese Adults: A Systematic Review

¹ University of Pittsburgh Medical Center St. Margaret, Pittsburgh, Pa
² Grace Medical Associates, Pittsburgh, Pa
³ University of Oklahoma-Tulsa, Tulsa, Okla

CORRESPONDING AUTHOR: Kara M. Levri, MD, MPH, UPMC St. Margaret, 3937 Butler St., Pittsburgh, PA 15201, kl55882{at}aol.com

ABSTRACT

PURPOSE We wanted to determine whether metformin is an effective medication for treatment of overweight or obese adults who do not have diabetes mellitus or polycystic ovary syndrome (PCOS).

METHODS We searched MEDLINE (1966–2003), EMBASE (1986–2003), Allied and Complementary Medicine Database (1985–2003), International Pharmaceutical Abstracts (1970–2003), the Cochrane Library, American College of Physicians Journal Club, Database of Abstracts of Reviews of Effects, Cochrane Controlled Trials Register, MEDLINE In-Process & Other Non-Indexed Citations, reference lists of retrieved articles, and articles by selected authors and pharmaceutical manufacturers. Inclusion criteria were being obese or overweight determined by a BMI of 25 kg/m² or greater or waist-to-hip ratio (WHR) of more than 0.8, metformin use, and aged 18 years or older. Exclusion criteria were a diagnosis of diabetes mellitus, polycystic ovarian syndrome or descriptors of polycystic ovarian syndrome, human immunodeficiency virus infection, and concomitant antipsychotic medications. Trials were graded on an 11-point Jadad scale. Only randomized controlled and blinded trials were accepted. Two reviewers independently extracted data from each trial. Primary outcomes measured were changes in BMI, WHR, and weight.

RESULTS Fifty-seven potentially relevant studies were initially identified; 48 were excluded because of lack of randomization, lack of blinding, failure to meet inclusion or exclusion criteria, inaccessible outcomes, or improper study design. Nine clinical trials met criteria for validity assessment. Four studies used the parameter of waist-to-hip ratio, 3 studies included BMI, and 8 used weight. Two of the 9 studies showed a small reduction in WHR.

CONCLUSION Insufficient evidence exists for the use of metformin as treatment of overweight or obese adults who do not have diabetes mellitus or polycystic ovary syndrome. Further studies are needed to answer this clinical question.

Key Words: Metformin • obesity • anti-obesity agents • body mass index

This article has been cited by other articles:

				A. R Desilets, S. Dhakal-Karki, and K. C Dunican Role of Metformin for Weight Management in Patients Without Type 2 Diabetes Ann. Pharmacother., June 1, 2008; 42(6): 817 - 826. [Abstract] [Full Text] [PDF]

				R. S. Legro A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome JAMA, February 7, 2007; 297(5): 509 - 519. [Abstract] [Full Text] [PDF]

				K. C. Stange Practical and Contextual Issues Ann. Fam. Med, November 1, 2005; 3(6): 556 - 557. [Full Text] [PDF]

				K. C. Stange In This Issue: Subtle Clinical Policy Ann. Fam. Med, September 1, 2005; 3(5): 386 - 388. [Full Text] [PDF]

TRACK Comments: